TD Cowen Maintains Veradigm(MDRX.US) With Buy Rating, Maintains Target Price $15
Veradigm (MDRX) Gets a Buy From TD Cowen
Veradigm Analyst Ratings
Buy Rating Affirmed for Veradigm: Growth Prospects and Market Position Highlighted
Deutsche Bank Downgrades Veradigm to Hold From Buy, Adjusts Price Target to $10 From $15
Veradigm Analyst Ratings
Veradigm's Challenging Outlook: Hold Rating Justified Amid Revenue Growth, Margin Pressures, and Audit Concerns
Analysts Conflicted on These Healthcare Names: Veradigm (OtherMDRX), ADC Therapeutics (ADCT) and Sangamo Biosciences (SGMO)
Veradigm Analyst Ratings
RBC Halves Price Target on Veradigm to $11 From $22, Keeps Outperform Rating
Barclays Starts Allscripts Healthcare Solutions With Equalweight Rating, $11 Price Target
Barclays Initiates Coverage On Veradigm With Equal-Weight Rating, Announces Price Target of $11
Veradigm Analyst Ratings
Deutsche Bank Adjusts Veradigm Price Target to $15 From $18, Maintains Buy Rating
Stephens & Co. Reiterates Equal-Weight on Veradigm, Maintains $13 Price Target
Veradigm Analyst Ratings
Stephens & Co. Reiterates Equal-Weight on Veradigm, Maintains $13 Price Target
Veradigm Analyst Ratings
Research Alert: CFRA Drops Analytical Coverage Of Veradigm Inc.
RBC Capital Reaffirms Their Buy Rating on Veradigm (MDRX)